Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 4/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | ITGA1 | P56199 | 2/20 | 0.41 |
| ▸ | EDNRA | P25101 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29519358 | 1.00 | TRPV4 (0.57) | TRPV4AKR1B1TP53TSHRMCL1 | |
| SCHEMBL6335085 | 0.83 | AKR1B1 (0.56) | TRPV4AKR1B1TP53TSHRMCL1 | |
| SCHEMBL198172 | 0.81 | MCL1 (0.55) | TRPV4AKR1B1TP53TSHRMCL1 | |
| Hydrochloric Acid SCHEMBL11256201 | 0.81 | AKR1B1 (0.54) | TRPV4AKR1B1TP53TSHRMCL1 | |
| SCHEMBL11963208 | 0.81 | AKR1B1 (0.46) | TRPV4AKR1B1TP53TSHRMCL1 | |
| SCHEMBL29386495 | 0.81 | MCL1 (0.55) | TRPV4AKR1B1TP53TSHRMCL1 | |
| SCHEMBL22808128 | 0.80 | TP53 (0.50) | TRPV4AKR1B1TP53TSHRMCL1 | |
| SCHEMBL3268704 | 0.79 | AKR1B1 (0.45) | TRPV4AKR1B1TP53TSHRMCL1 | |
| SCHEMBL6915021 | 0.79 | HSD11B1 (0.45) | TRPV4AKR1B1TP53TSHRMCL1 | |
| SCHEMBL1729184 | 0.79 | HSD11B1 (0.45) | TRPV4AKR1B1TP53TSHRMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 824 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162883-B2 | Process for the preparation of intermediates useful for making (2S,5R)-7-oxo-n-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide | MERCK SHARP & DOHME LLC (US) | 2024-12-10 | — | — | US | claimed |
| US-20220194941-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR MAKING (2S,5R)-7-OXO-N-PIPERIDIN-4-YL-6-(SULFOXY)-l,6-DIAZABICYCLO[3.2.1]OCTANE-2-CARBOXAMIDE | MERCK SHARP & DOHME CORP. (US) | 2022-06-23 | — | — | US | claimed |
| CN-114206851-A | Process for the preparation of intermediates useful in the preparation of (2S,5R) -7-oxo-N-piperidin-4-yl-6- (sulfate) -1, 6-diazabicyclo [3.2.1] octane-2-carboxamide | 默沙东公司 | 2022-03-18 | — | — | CN | claimed |
| EP-3959205-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR MAKING (2S,5R)-7-OXO-N-PIPERIDIN-4-YL-6-(SULFOXY)-1,6-DIAZABICYCLO[3.2.1]OCTANE-2-CARBOXAMIDE | Merck Sharp & Dohme Corp. (US) | 2022-03-02 | — | — | EP | claimed |
| WO-2020219405-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR MAKING (2S,5R)-7-OXO-N-PIPERIDIN-4-YL-6-(SULFOXY)-1,6-DIAZABICYCLO[3.2.1]OCTANE-2-CARBOXAMIDE | MERCK SHARP & DOHME CORP. (US) | 2020-10-29 | — | — | WO | claimed |
| WO-2013102936-A1 | N-(3-((DIETHYLAMINO) METHYL)-4-HYDROXYPHENYL)-N-(QUINOLIN-4-YL) SULFONAMIDES FOR THE TREATMENT OF TUBERCULOSIS AND PROCESS OF PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-07-11 | — | — | WO | claimed |
| EP-1677797-B1 | SALTS AND POLYMORPHS OF A POTENT ANTIDIABETIC COMPOUND | AMGEN INC (US) | 2012-02-22 | — | — | EP | claimed |
| EP-1677797-A4 | SALTS AND POLYMORPHS OF A POTENT ANTIDIABETIC COMPOUND | AMGEN INC (US) | 2009-03-25 | — | — | EP | claimed |
| US-7223761-B2 | Salts and polymorphs of a potent antidiabetic compound | AMGEN INC. (US) | 2007-05-29 | — | — | US | claimed |
| EP-1677797-A2 | SALTS AND POLYMORPHS OF A POTENT ANTIDIABETIC COMPOUND | Amgen Inc. (US) | 2006-07-12 | — | — | EP | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| US-20050143416-A1 | Salts and polymorphs of a potent antidiabetic compound | AMGEN INC. | 2005-06-30 | — | — | US | claimed |
| WO-2005033074-A2 | SALTS AND POLYMORPHS OF A POTENT ANTIDIABETIC COMPOUND | AMGEN, INC. (US) | 2005-04-14 | — | — | WO | claimed |
| EP-3802500-B1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | disclosed |
| WO-2026099404-A1 | SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | QUBIT PHARMACEUTICALS (FR) | 2026-05-15 | — | — | WO | disclosed |
| US-4164395-A | USING A SULFONYL OXIME AS ACTIVATOR | FMC CORPORATION (US) | 1979-08-14 | — | — | US | disclosed |
| US-4117154-A | INSECTICIDES, ACARICIDES, NEMATOCIDES, FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1978-09-26 | — | — | US | disclosed |
| US-4052395-A | AGRICULTURAL FUNGICIDAL COMPOSITIONS CONTAINING 6-(SUBSTITUTED PHENYL)-PYRIDAZINONES AND SAID PYRIDAZINONES | SANKYO COMPANY LIMITED (JA) | 1977-10-04 | — | — | US | disclosed |
| US-4041051-A | 1-AMINO-4-HYDROXY-2-(P-METHOXY OR ETHOXY-BENZENESULFONYLOXY)-ANTHRAQUINONE | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | TRPV4 2630/4885AKR1B1 1366/4885TP53 4741/4885 |
| US-20220194941-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR MAKING (2S,5R)-7-OXO-N-PIPERIDIN-4-YL-6-(SULFOXY)-l,6-DIAZABICYCLO[3.2.1]OCTANE-2-CARBOXAMIDE | OGA, SULT1E1, UCHL5 | TRPV4 4827/4885AKR1B1 1658/4885TP53 4807/4885 |
| US-20050143416-A1 | Salts and polymorphs of a potent antidiabetic compound | PPARD, PPARA, PPARG | TRPV4 730/4885AKR1B1 336/4885TP53 1209/4885 |
| US-12162883-B2 | Process for the preparation of intermediates useful for making (2S,5R)-7-oxo-n-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide | SULT1E1, OGA, SULT1A1 | TRPV4 4828/4885AKR1B1 1576/4885TP53 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.